Bisphosphonate Treatment of Osteogenesis Imperfecta
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to evaluate whether the investigational medication is
safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta
(OI) patients.